Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)

DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares DBV Technologies and Arrowhead Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	N/A	N/A	-$146.95 million	($3.51)	-2.70
Arrowhead Pharmaceuticals	$829.45 million	10.01	-$1.63 million	($2.25)	-26.19

Arrowhead Pharmaceuticals has higher revenue and earnings than DBV Technologies. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

DBV Technologies has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Insider and Institutional Ownership

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares DBV Technologies and Arrowhead Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Analyst Ratings

This is a summary of current ratings and price targets for DBV Technologies and Arrowhead Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1	0	5	0	2.67
Arrowhead Pharmaceuticals	1	3	10	1	2.73

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 411.60%. Arrowhead Pharmaceuticals has a consensus target price of $99.07, suggesting a potential upside of 68.15%. Given DBV Technologies’ higher possible upside, analysts plainly believe DBV Technologies is more favorable than Arrowhead Pharmaceuticals.

Summary

Arrowhead Pharmaceuticals beats DBV Technologies on 11 of the 14 factors compared between the two stocks.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.